Matt McNally, CEO of Outcome Health, shares his thoughts on post-controversy Outcome Health and the overall state of the point-of-care union.
Among the group's members are media agencies that had pulled healthcare ad spend from the POC channel in the wake of a scandal 10 months ago.
GSW's creative council met for an honest discussion about the agency-client relationship, the tension between data and emotional connection, industry trends, and creativity in the face of regulation.
Gilead appoints new commercial lead; U.K. bans online ad for contraception app; Pfizer petitions the FDA to clarify biosimilar communications.
Some of the advertising industry's top analysts say Mark Read looks the best choice to be WPP's chief executive and the board would need to find a "spectacular" alternative.
Gilead's CAR-T cell therapy ruled too expensive in the U.K.; Experts mixed on impact of drug price hike freezes; Women turn to wearables for fertility tracking
Some of the world's most powerful pharmaceutical companies backed down on planned price increases following a new transparency law in California and social media hectoring from President Donald Trump.
Pfizer's drug tafamidis reduces risk of death; Lilly Diabetes pulls its sponsorship of Daly's car; FDA investigates electronic cigarette maker Juul.
Chase Design Group's John Tanner shares what he thinks brands can do to spice things up when it comes to marketing around marijuana.
As more medications are approved, pharma companies are being pushed farther afield into a land of bizarre — but hopefully still memorable and vaguely meaningful — drug names.
White House proposes rule for drug prices in DTC ads; FDA to study impact of side-effects warnings in drug ads; FDA approves Shire's potential blockbuster HAE treatment.
The companies plan to make the most of favorable market access conditions for the at-home colon cancer screening test.
Biosimilars have only been in the market for three years, but they have struggled to compete with their branded equivalents.